Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-leucine is the biologically active, naturally occurring enantiomer of leucine, an essential branched-chain amino acid (BCAA) with the molecular formula C6H13NO2. It is a non-polar, aliphatic amino acid characterized by an isobutyl side chain and plays a critical role in protein biosynthesis and muscle metabolism. As one of the three BCAAs, l-leucine cannot be synthesized by humans and must be obtained from dietary sources such as meat, dairy products, soy products, and legumes[2][3][6]. Its primary mechanism of action involves direct stimulation of myofibrillar muscle protein synthesis through activation of the mechanistic target of rapamycin (mTOR) pathway[2][5]. This effect makes it vital for muscle growth, repair, maintenance, and recovery. Additionally, l-leucine has been investigated for therapeutic use in conditions like sarcopenia and cachexia due to its anabolic effects on skeletal muscle[5]. It is widely used as a dietary supplement in sports nutrition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on l-leucine.